Nolvadex generic distribution by Barr to end
Executive Summary
Barr's distribution of "authorized" Nolvadex generic will not extend through AstraZeneca's pediatric exclusivity, which began Aug. 20. Barr will distribute its remaining inventories, but the end of discussions on an extension raises possibility the brand could be the only product on the market until exclusivity expires in February. Barr and FDA continue to negotiate the company's right to launch its own tamoxifen during pediatric exclusivity in light of tentative approval granted before passage of pediatric exclusivity legislation (1"The Pink Sheet" Aug. 19, p. 12)...
You may also be interested in...
Barr generic tamoxifen
Barr expects answer from FDA in mid-September regarding its right to manufacture generic tamoxifen. Barr is distributing an "authorized" generic of Nolvadex under license from AstraZeneca, and the generic company claims it is entitled to launch its own version before the brand's pediatric exclusivity expires in February. Barr may exhaust its existing inventory of tamoxifen in early November according to one estimate; it appears unlikely AstraZeneca will extend the supply agreement through the pediatric exclusivity period (1"The Pink Sheet" Aug. 26, In Brief)...
Barr Seeking To Launch Generic Tamoxifen During Pediatric Exclusivity
Barr is in negotiations with FDA regarding its right to launch a generic tamoxifen during AstraZeneca's pediatric exclusivity for Nolvadex
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.